Anuh Pharma reported strong revenue growth of 16% to ₹776.01 crore for FY26. However, profitability declined, with Profit After Tax falling to ₹41.05 crore from ₹47.35 crore in the previous year.
Anuh Pharma Posts 16% Revenue Growth in FY26, Profit Declines Amid Capacity Expansion
Total Revenue (FY26): ₹776.01 crore
Profit After Tax (FY26): ₹41.05 crore
Reader Takeaway: Revenue grew 16% but margins compressed, leading to lower profits; capacity expansion is underway.
What just happened
Anuh Pharma reported its financial results for the fiscal year 2025-26. The company achieved a total revenue of ₹776.01 crore, marking a 16% increase from ₹670.97 crore in FY 2024-25. However, profitability saw a decline. Profit After Tax (PAT) for FY26 stood at ₹41.05 crore, down from ₹47.35 crore in the previous year. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) also decreased to ₹66.08 crore from ₹70.36 crore.
Why this matters
The results show a mixed performance for Anuh Pharma. While the company successfully grew its top line, driven by capacity expansion and new product launches, the dip in profitability indicates potential margin pressures. This could be due to factors like rising input costs, increased competition, or a shift in product mix. Investors will watch how the company navigates these pressures while pursuing growth.
The backstory
Anuh Pharma has been focusing on expanding its operational capacity and product portfolio. The company recently inaugurated the INT-1A manufacturing block in July 2025, adding 200 MT/annum capacity. It also launched six new products in FY26, targeting therapeutic areas like Diabetes, Hypertension, CNS, and Dermatology.
What changes now
The company has provided a positive outlook for FY 2026-27, expecting revenue growth between 15-20%. Management also indicated an interest in exploring inorganic growth opportunities through mergers and acquisitions. Additionally, the Board of Directors has recommended a final dividend of ₹1.50 per equity share for FY26, subject to shareholder approval.
Risks to watch
Management highlighted potential challenges in the global API industry, including surplus capacities and geopolitical uncertainties. Profit margin pressure, evident in the FY26 results, remains a key concern. Investors should monitor input cost fluctuations and competitive pricing.
Peer comparison
Anuh Pharma operates in the Active Pharmaceutical Ingredients (API) sector. While specific peer financial data for FY26 is not provided in the filing, the sector generally faces pricing pressures and regulatory scrutiny globally.
Context metrics (time-bound)
- Revenue Growth: 16% Year-over-Year (FY26 vs FY25).
- PAT Decline: Approximately 13% Year-over-Year (FY26 vs FY25).
- EBITDA Decline: Approximately 6% Year-over-Year (FY26 vs FY25).
- Installed Capacity: 2,400 MTPA (API and intermediate blocks).
- New Capacity Added: 200 MTPA (INT-1A block in July 2025).
What to track next
Investors should track the company's performance against its FY 2026-27 guidance of 15-20% revenue growth. Monitoring improvements in EBITDA and PAT margins will be crucial to assess the company's ability to manage costs and competition effectively. Any updates on potential mergers or acquisitions will also be significant.